Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer | Zendy

Matthew Kaag | Zendy; Jay D. Raman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer

Author(s) -

Matthew Kaag,

Jay D. Raman

Publication year - 2018

Publication title -

translational andrology and urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.721

H-Index - 27

eISSN - 2223-4691

pISSN - 2223-4683

DOI - 10.21037/tau.2018.09.03

Subject(s) - cystectomy , bladder cancer , medicine , perioperative , cisplatin , urology , dissection (medical) , lymph node , complication , gold standard (test) , chemotherapy , sarcopenia , surgery , cancer

Radical cystectomy (RC) with pelvic lymph node dissection, preceded by cisplatin-based neoadjuvant chemotherapy in appropriate patients, remains the gold-standard in the treatment of muscle invasive bladder cancer (MIBC) (1,2). RC is a complex operation performed in an elderly (and sometimes unhealthy) patient population, with significant complication rates (as high as 60%) and perioperative mortality rates (9%) reported at 90-days (3,4).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research